Regulus Therapeutics (NASDAQ:RGLS) Rating Lowered to Hold at Leerink Partnrs

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) was downgraded by research analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Wednesday, April 30th,Zacks.com reports.

Several other brokerages also recently commented on RGLS. Canaccord Genuity Group reiterated a "hold" rating and set a $11.00 target price (down from $28.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Jones Trading reaffirmed a "hold" rating and set a $7.00 price target (down previously from $8.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Wells Fargo & Company reissued an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Leerink Partners reissued a "market perform" rating and issued a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $8.50.

Regulus Therapeutics Trading Up 0.2 %

Shares of Regulus Therapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $7.85. The stock had a trading volume of 301,123 shares, compared to its average volume of 870,092. The firm has a market capitalization of $519.68 million, a price-to-earnings ratio of -7.33 and a beta of 0.49. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $8.20. The firm has a 50 day simple moving average of $2.37 and a two-hundred day simple moving average of $1.75.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). During the same quarter in the previous year, the company earned ($0.40) EPS. Sell-side analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Barclays PLC boosted its holdings in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 52,059 shares during the period. Jane Street Group LLC bought a new stake in shares of Regulus Therapeutics during the 3rd quarter valued at about $46,000. PEAK6 LLC acquired a new stake in Regulus Therapeutics during the fourth quarter worth about $95,000. Finally, Renaissance Technologies LLC boosted its stake in Regulus Therapeutics by 20.5% in the fourth quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock valued at $185,000 after acquiring an additional 19,900 shares during the period. Institutional investors own 92.38% of the company's stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.